Vericel Corp (VCEL) stock
VCELNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 16/30254% above fair value
$57.42−2.03 (-3.41%)
Close on Nov 12, 2026Market cap $2.94BP/E 97.3Yield –
Vericel r&d expenses
Research and development expenses are spending on new products and technology.
Vericel's R&D Expenses for the twelve months ending Sep 30, 2026 was $29.74M, up 17.8% year over year. For fiscal 2025 it was $27.56M, up 11.2% from the year before. Over ten years it grew 3.9% a year on average. The highest annual figure on record is $30.39M in fiscal 2019.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $27.56M | +11.2% |
| FY2024 | Dec 31, 2024 | $24.80M | +17.8% |
| FY2023 | Dec 31, 2023 | $21.04M | +5.5% |
| FY2022 | Dec 31, 2022 | $19.94M | +22.4% |
| FY2021 | Dec 31, 2021 | $16.29M | +25.1% |
| FY2020 | Dec 31, 2020 | $13.02M | -57.2% |
| FY2019 | Dec 31, 2019 | $30.39M | +123.5% |
| FY2018 | Dec 31, 2018 | $13.60M | +5.1% |
| FY2017 | Dec 31, 2017 | $12.94M | -15.4% |
| FY2016 | Dec 31, 2016 | $15.30M | -19.0% |
| FY2015 | Dec 31, 2015 | $18.89M | -11.2% |
| FY2014 | Dec 31, 2014 | $21.26M | +40.8% |
| FY2013 | Dec 31, 2013 | $15.10M | -42.0% |
| FY2012 | Dec 31, 2012 | $26.03M | +105.6% |
| FY2010 | Jun 30, 2010 | $12.66M | +12.1% |
| FY2009 | Jun 30, 2009 | $11.29M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $6.89M | +9.0% |
| Q2 FY2026 | Jun 30, 2026 | $7.49M | +11.3% |
| Q1 FY2026 | Mar 31, 2026 | $8.10M | +11.6% |
| Q4 FY2025 | Dec 31, 2025 | $7.25M | +47.3% |
| Q3 FY2025 | Sep 30, 2025 | $6.32M | +3.7% |
| Q2 FY2025 | Jun 30, 2025 | $6.73M | -8.6% |
| Q1 FY2025 | Mar 31, 2025 | $7.26M | +13.1% |
| Q4 FY2024 | Dec 31, 2024 | $4.92M | +0.4% |
| Q3 FY2024 | Sep 30, 2024 | $6.09M | +7.3% |
| Q2 FY2024 | Jun 30, 2024 | $7.36M | +40.2% |
| Q1 FY2024 | Mar 31, 2024 | $6.42M | +23.1% |
| Q4 FY2023 | Dec 31, 2023 | $4.90M | -6.6% |
| Q3 FY2023 | Sep 30, 2023 | $5.68M | +12.5% |
| Q2 FY2023 | Jun 30, 2023 | $5.25M | +9.6% |
| Q1 FY2023 | Mar 31, 2023 | $5.21M | +7.2% |
| Q4 FY2022 | Dec 31, 2022 | $5.25M | +33.7% |
| Q3 FY2022 | Sep 30, 2022 | $5.05M | +17.8% |
| Q2 FY2022 | Jun 30, 2022 | $4.79M | +7.7% |
| Q1 FY2022 | Mar 31, 2022 | $4.86M | +33.9% |
| Q4 FY2021 | Dec 31, 2021 | $3.92M | +25.8% |
| Q3 FY2021 | Sep 30, 2021 | $4.28M | +47.1% |
| Q2 FY2021 | Jun 30, 2021 | $4.45M | +37.9% |
| Q1 FY2021 | Mar 31, 2021 | $3.63M | -3.5% |
| Q4 FY2020 | Dec 31, 2020 | $3.12M | -3.1% |
| Q3 FY2020 | Sep 30, 2020 | $2.91M | -5.9% |
| Q2 FY2020 | Jun 30, 2020 | $3.23M | -84.7% |
| Q1 FY2020 | Mar 31, 2020 | $3.76M | +25.1% |
| Q4 FY2019 | Dec 31, 2019 | $3.22M | +6.6% |
| Q3 FY2019 | Sep 30, 2019 | $3.10M | -0.5% |
| Q2 FY2019 | Jun 30, 2019 | $21.07M | +463.5% |
| Q1 FY2019 | Mar 31, 2019 | $3.01M | -19.3% |
| Q4 FY2018 | Dec 31, 2018 | $3.02M | -15.9% |
| Q3 FY2018 | Sep 30, 2018 | $3.11M | +6.6% |
| Q2 FY2018 | Jun 30, 2018 | $3.74M | +25.8% |
| Q1 FY2018 | Mar 31, 2018 | $3.73M | +7.6% |
| Q4 FY2017 | Dec 31, 2017 | $3.59M | -15.8% |
| Q3 FY2017 | Sep 30, 2017 | $2.92M | – |
| Q2 FY2017 | Jun 30, 2017 | $2.97M | – |
| Q1 FY2017 | Mar 31, 2017 | $3.47M | – |
| Q4 FY2016 | Dec 31, 2016 | $4.26M | – |
See a number that looks wrong?